ZemiSU (gemigliptin/glimepiride) / LG Chem - LARVOL DELTA

Comparison of the effects of gemigliptin versus glimepiride on cardiac function in patients with type 2 diabetes uncontrolled with metformin: the Gemi-Heart study. (PubMed, Diabetes Obes Metab) - P4 | "Gemigliptin had a comparable glucose-lowering efficacy without deleterious effects on cardiac functions or on biomarkers reflective of myocardial injury or heart failure during the 24-week observation period. However, larger, longer-term studies are needed to confirm these findings."

Journal • Cardiovascular • Congestive Heart Failure • Diabetes • Dyslipidemia • Heart Failure • Metabolic Disorders • Type 2 Diabetes Mellitus • CRP

Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study. (PubMed, Nutrients) - "However, regardless of the treatment modality, a distinct difference in the overall gut microbiome composition was noted between patients who reached the HbA1c target goal and those who did not (p < 0.001). Treatment with gemigliptin-metformin resulted in a higher achievement of the glycemic target without hypoglycemia or weight gain, better than with glimepiride-metformin; these improvements might be related to beneficial changes in gut microbiota."

Journal • Diabetes • Hypoglycemia • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Effect of Gemigliptin Versus Glimepiride on Cardiac Diastolic Function in Patients With Type 2 Diabetes (clinicaltrials.gov) - P4 | N=80 | Recruiting | Sponsor: Seoul National University Bundang Hospital

New P4 trial • Congestive Heart Failure • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • CRP • RETN

Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis. (PubMed, Endocrinol Metab (Seoul)) - "Four had an active control group (ACG), with metformin/dapagliflozin/sitagliptin/glimepiride as the active comparator; six had a passive control group (PCG), with placebo/rosuvastatin as controls...The gemigliptin group did not have increased hypoglycaemia (RR, 1.19; 95% CI, 0.62 to 2.28; P=0.61; I2=19%; HCE). Gemigliptin has good glycaemic efficacy and is well-tolerated over 6 months of use."

Journal • Retrospective data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus